Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New anti-malaria drug

15.02.2002


The malaria parasite multiplies in red blood cells, safe from our immune defences
© SPL


Monkey tests hint compound could paralyse malaria parasite in humans.

A new-found chemical can root out malaria parasites hiding in red blood cells and stop them reproducing. It may become a much-needed new weapon in the war against one of the world’s biggest killers.

The compound clears monkeys of infection with the human malaria parasite Plasmodium falciparum at doses far lower than existing antimalarial drugs. But testing in humans is a few years away at least, says Henri Vial at Montpellier University in France who discovered the 1.



Developing new antimalarials is essential: malaria kills more than one million people each year, and the parasites are becoming resistant to existing drugs.

Malaria parasites enter our blood when the mosquitoes that carry them bite us. The parasites multiply inside red blood cells, safe from the body’s immune system.

Vial’s team developed a range of compounds that interfere with the building of cell membranes. Rapidly reproducing parasites are constantly making new cell membranes.

They used infected human blood samples to screen all their chemicals for antimalarial activity. A compound with the working name G25 came out on top.

"We were very lucky," says Vial: G25 only enters red-blood cells that harbour reproducing malaria parasites. Why is a mystery, and "the focus of our research now", Vial says.

This selectivity is important for two reasons. First, because all animal cells make membranes, G25 would be highly toxic if it were less discerning. More importantly, scientists could exploit the chemical’s nose for malaria-infected cells to deliver other antimalarial compounds. "It is a natural targeting mechanism," Vial says.

"No other group of drugs works like this," says Peter Winstanley, who is developing new antimalarial drugs at the University of Liverpool in England. As a result, he hopes G25 could kill even drug-resistant malaria.

But because G25 acts on a fundamental biological system there could be harmful side-effects. Vial’s team saw nothing untoward in monkeys, but admits more work on the safety of the compound is needed.

Another big hurdle is getting the compound into pill form. Currently it has to be injected. "We do have problems with oral absorption," says Vial. Chemical tweaking of G25 should help.

Scientific obstacles aside, new malaria drugs face an uphill economic struggle, cautions Winstanley. To save the most lives, malaria drugs must be affordable for developing countries where the disease is endemic. Keeping development costs low enough to achieve this is hard.

The newest antimalarial drug on the market costs $57 for a course of treatment. For the developing world "it would need to cost a lot less than 50 cents", Winstanley says.

References

  1. Wengelnik, K. et al. A class of potent antimalarials and their specific accumulation on infected erythrocytes. Science, 295, 1311 - 1314, (2002).

TOM CLARKE | © Nature News Service
Further information:
http://www.nature.com/nsu/020211/020211-11.html

More articles from Health and Medicine:

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

nachricht Distrust of power influences choice of medical procedures
01.08.2018 | Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

Im Focus: A molecular switch may serve as new target point for cancer and diabetes therapies

If certain signaling cascades are misregulated, diseases like cancer, obesity and diabetes may occur. A mechanism recently discovered by scientists at the Leibniz- Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and at the University of Geneva has a crucial influence on such signaling cascades and may be an important key for the future development of therapies against these diseases. The results of the study have just been published in the prestigious scientific journal 'Molecular Cell'.

Cell growth and cell differentiation as well as the release and efficacy of hormones such as insulin depend on the presence of lipids. Lipids are small...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

NRL's sun imaging telescopes fly on NASA Parker Solar Probe

13.08.2018 | Physics and Astronomy

UT-ORNL team makes first particle accelerator beam measurement in six dimensions

13.08.2018 | Physics and Astronomy

ASU astrophysicist helps discover that ultrahot planets have starlike atmospheres

13.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>